The dual PI3K/mTOR inhibitor NVP-BEZ235 enhances nab-paclitaxel antitumor response in experimental gastric cancer. - Wikidata - wikimedia - TriplyDB

The dual PI3K/mTOR inhibitor NVP-BEZ235 enhances nab-paclitaxel antitumor response in experimental gastric cancer.

The dual PI3K/mTOR inhibitor NVP-BEZ235 enhances nab-paclitaxel antitumor response in experimental gastric cancer.

http://www.wikidata.org/entity/Q34086875

about

Targeting the PI3K/Akt signaling pathway in gastric carcinoma: A reality for personalized medicine?Genomic assays for Epstein-Barr virus-positive gastric adenocarcinoma Oleanolic acid suppresses aerobic glycolysis in cancer cells by switching pyruvate kinase type M isoforms SPAG5 upregulation predicts poor prognosis in cervical cancer patients and alters sensitivity to taxol treatment via the mTOR signaling pathway.The Role of PI3K/Akt/mTOR Signaling in Gastric Carcinoma.AKT/ERK activation is associated with gastric cancer cell resistance to paclitaxel.Synergistic inhibition of colon cancer cell growth with nanoemulsion-loaded paclitaxel and PI3K/mTOR dual inhibitor BEZ235 through apoptosis.Association between PIK3CA alteration and prognosis of gastric cancer patients: a meta-analysis.Bioinformatic Analysis of GLI1 and Related Signaling Pathways in Chemosensitivity of Gastric Cancer.

P2860

Q26775940-71239B0B-ADAA-42D2-A6F8-053ED149A589 Q27024034-5A184B77-BB72-43E7-A536-81573C50E377 Q28540878-0F26EAB0-8CC8-4EFE-9F0B-EF950A79F60F Q33720115-D9D1E2D6-826D-45F2-BFCA-73CF7C5E2D9F Q34309903-18BAD0BB-FE41-484A-8C93-0531B8CDD39B Q38996033-8A807108-FFDC-4AB9-AF98-D318ED0272F7 Q39735209-D945356B-24A1-4978-8290-26A2886A5926 Q50299737-0CB59D13-150E-4778-95B7-6674AF9F1F4A Q52622142-384F3DE4-E457-4F4F-8B09-8EB7ADDD055E

P2860

The dual PI3K/mTOR inhibitor NVP-BEZ235 enhances nab-paclitaxel antitumor response in experimental gastric cancer.

http://www.wikidata.org/entity/Q34086875

description

2013 nî lūn-bûn

@nan

2013 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

The dual PI3K/mTOR inhibitor N ...... n experimental gastric cancer.

@ast

The dual PI3K/mTOR inhibitor N ...... n experimental gastric cancer.

@en

The dual PI3K/mTOR inhibitor N ...... n experimental gastric cancer.

@nl

type

label

The dual PI3K/mTOR inhibitor N ...... n experimental gastric cancer.

@ast

The dual PI3K/mTOR inhibitor N ...... n experimental gastric cancer.

@en

The dual PI3K/mTOR inhibitor N ...... n experimental gastric cancer.

@nl

prefLabel

The dual PI3K/mTOR inhibitor N ...... n experimental gastric cancer.

@ast

The dual PI3K/mTOR inhibitor N ...... n experimental gastric cancer.

@en

The dual PI3K/mTOR inhibitor N ...... n experimental gastric cancer.

@nl

P1433

Q34086875-39D6821A-86BE-4445-80AC-99C25B0CAFE6

P1476

Q34086875-6FEC2C63-7848-4F93-A925-E59D1E15C7EE

P2093

Q34086875-1D9EB256-2B29-487E-A106-F5E3946C0D1E

Q34086875-2F946538-D306-4143-84EA-597883F8019E

Q34086875-5B834840-CB1B-4D1F-A2A9-58973CACAE28

Q34086875-76182736-18ED-421C-9D99-9B94C821EB6A

P2860

Q34086875-003D7718-CDDA-4149-B25F-7B60769107FA

Q34086875-06ECD5EA-2DE8-4271-BA2C-619EE380CD0A

Q34086875-071FEBBA-2DAF-4B7C-B07D-EBB62C979FA7

Q34086875-0891B911-0A56-4390-981F-17527E421FCE

Q34086875-0BC578FE-F2C1-4A4A-A2D7-B19AFF6EF813

Q34086875-0E611878-E270-48CE-878F-72B9324F4191

Q34086875-1C43373A-C2DC-4EE5-8A48-F39ABBC536E2

Q34086875-2F80B75D-AFBC-488B-A937-D53479C5BAA7

Q34086875-38C7079D-78C8-4B9A-A05A-40D89BF59F98

Q34086875-3940798D-272D-4C63-98C5-EF365CFD8A0F

P304

Q34086875-5CA87C27-E436-4B9B-8488-F1CAFD465687

P31

Q34086875-860C375D-CBC3-4357-AEC6-4F1E12A93AA6

P356

Q34086875-49F85C1C-EE32-4418-B22A-68A7B31A2B03

P433

Q34086875-A67925D2-F085-4078-A0C9-9E5AFF99735D

P478

Q34086875-D6259203-6FB0-4139-BB0D-6D2DBC4A22FD

P577

Q34086875-6C2E9B64-268C-4FD8-BF66-9082120F5115

P5875

Q34086875-7A013D5E-00CD-4981-8272-0E1C44FB69E6

P698

Q34086875-CC7440E4-194F-453B-9200-EFDD4AB97525

P932

Q34086875-FEC38E15-433B-49DD-AE4E-BCC958D4D499

P356

P1433

International Journal of Oncology

P1476

The dual PI3K/mTOR inhibitor N ...... n experimental gastric cancer.

@en

P2093

Chang-Ηua Zhang

http://www.w3.org/2001/XMLSchema#string

Margaret A Schwarz

http://www.w3.org/2001/XMLSchema#string

Niranjan Awasthi

http://www.w3.org/2001/XMLSchema#string

Roderich E Schwarz

http://www.w3.org/2001/XMLSchema#string

P2860

Mutations of PIK3CA in gastric adenocarcinoma

Global cancer statistics

Mitotic checkpoint slippage in humans occurs via cyclin B destruction in the presence of an active checkpoint.

Inhibitors of phosphatidylinositol 3'-kinases promote mitotic cell death in HeLa cells

NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.

Albumin-bound paclitaxel: a next-generation taxane

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study

A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group Study, N057E(1)

P304

1627-1635

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/IJO.2013.2099

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

43

http://www.w3.org/2001/XMLSchema#string

P577

2013-09-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

256664971

http://www.w3.org/2001/XMLSchema#string

P698

24042258

http://www.w3.org/2001/XMLSchema#string

P932

4144025

http://www.w3.org/2001/XMLSchema#string